Apogee Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Checking your notes…
Trading Plans
During the fiscal quarter ended September 30, 2025, no director or Section 16 officer adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K), except as described below.
On August 13, 2025, Dr. Michael Henderson, the Company's Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 340,000 shares of our common stock over a period ending July 9, 2026, subject to certain conditions.
On September 22, 2025, Dr. Carl Dambkowski, the Company's Chief Medical Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 132,000 shares of our common stock over a period ending January 7, 2027, subject to certain conditions.
On September 2, 2025, Jane Pritchett Henderson, the Company's Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 20,000 shares of our common stock over a period ending December 31, 2026, subject to certain conditions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.